# Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder

> **NCT02466477** · PHASE4 · COMPLETED · sponsor: **Assurex Health Inc.** · enrollment: 542 (actual)

## Conditions studied

- Depressive Disorder, Major
- Depression
- Depressive Disorder

## Interventions

- **GENETIC:** GeneSight Psychotropic (GEN)
- **GENETIC:** Enhanced-GeneSight Psychotropic (E-GEN)
- **OTHER:** Treatment as Usual (TAU)

## Key facts

- **NCT ID:** NCT02466477
- **Lead sponsor:** Assurex Health Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2018-11
- **Final completion:** 2019-09
- **Target enrollment:** 542 (ACTUAL)
- **Last updated:** 2020-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02466477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02466477, "Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02466477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*